Multimodality therapy and significance of serum CYFRA21-1 for thymic carcinoma

Oncology Reports

Volumn 13, Issue 6, 2005, Pages 1127-1131

  Suzuki, Makoto ^a,b   Ando, Soichiro ^a   Iida, Tomohiko ^a,b   Fujisawa, Takehiko ^b   Kimura, Hideki ^a  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

CYFRA21 1; Multimodality treatment; Prognosis; Thymic carcinoma; Tumor marker

Indexed keywords

ANTIGEN CYFRA21.1; ANTINEOPLASTIC AGENT; KERATIN; TUMOR ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLOOD; CANCER STAGING; DISEASE COURSE; FEMALE; HUMAN; MALE; MEDIASTINUM TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIATION DOSE; SURVIVAL RATE; THYMOMA; TREATMENT OUTCOME;

AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; KERATINS; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; THYMOMA; THYMUS NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 24744458644     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.6.1127     Document Type: Article

References (24)

1. Chung DA: Thymic carcinoma - analysis of nineteen clinicopathological studies. Thorac Cardiovasc Surg 48: 114-119, 2000.
2. Carlson RW, Dorfman RF and Sikic BI: Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Cancer 66: 2092-2094 1990.
3. Loehrer PJ Sr, Jiroutek M, Aisner S, et al: Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial Cancer 91: 2010-2015, 2001. (Pubitemid 32476364)
4. Yano T, Hara N, Ichinose Y, Asoh H, Yokoyama H and Ohta M: Treatment and prognosis of primary thymic carcinoma. J Surg Oncol 52: 255-258, 1993. (Pubitemid 23121943)
5. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, Connolly G, Debb G and Ramnath N: Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. Am J Clin Oncol 27: 68-72, 2004. (Pubitemid 38176294)
6. Blumberg D, Burr ME, Bains MS, et al: Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 115: 303-309, 1998. (Pubitemid 28093744)
7. Masaoka A, Yamakawa Y and Fujii Y: Well-differentiated thymic carcinoma: is it thymic carcinoma or not? J Thorac Cardiovasc Surg 117: 628-630, 1999.
8. Masaoka A, Monden Y, Nakahara K and Tanioka T: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48: 2485-2492, 1981. (Pubitemid 12228012)
9. Liu HC, Hsu WH, Chen YJ, et al: Primary thymic carcinoma. Ann Thorac Surg 73: 1076-1081, 2002.
10. Tomita M, Matsuzaki Y, Edagawa M, et al: Clinical and immunohistochemical study of eight cases with thymic carcinoma. BMC Surg 2: 3, 2002.
11. Lucchi M, Mussi A, Basolo F, Ambrogi MC, Fontanini G and Angeletti CA: The multimodality treatment of thymic carcinoma Eur J Cardiothorac Surg 19: 566-569, 2001. (Pubitemid 32416604)
12. Lucchi M, Mussi A, Ambrogi M, et al: Thymic carcinoma: a report of 13 cases. Eur J Surg Oncol 27: 636-640, 2001. (Pubitemid 33062170)
13. Gehan EA and Tefft MC: Will there be resistance to the RECIST (response evaluation criteria in solid tumors)? J Natl Cancer Inst 92: 179-181, 2000. (Pubitemid 30099776)
14. Ando S, Kimura H, Iwai N, Yamamoto N and Iida T: Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer. Anticancer Res 23: 2869-2874, 2003. (Pubitemid 36969825)
15. Johnson SB, Eng TY, Giaccone G and Thomas CR Jr: Thymoma: update for the new millennium. Oncologist 6: 239-246, 2001.
16. Wick MR, Scheithauer BW, Weiland LH and Bernatz PE: Primary thymic carcinomas. Am J Surg Pathol 6: 613-630, 1982. (Pubitemid 13234758)
17. Sasaki H, Yukiue H, Kobayashi Y, et al: Elevated serum pro-MMP2 levels in patients with stage IV thymoma. Surg Today 32: 482-486, 2002. (Pubitemid 34810731)
18. Suzuki K, Tanaka H, Shibusa T, et al: Parathyroid-hormone-related- protein-producing thymic carcinoma presenting as a giant extrathoracic mass. Respiration 65: 83-85, 1998. (Pubitemid 28076130)
19. Ikeda T, Kawakami K, Fujita J, Bandoh S, Yamadori I and Takahara J: Thymic carcinoma associated with a high serum level of interleukin 6 diagnosed through the evaluation for asymptomatic elevation of acute-phase reactants. Intern Med 37: 414-416, 1998. (Pubitemid 28303875)
20. Smith MD, Christiansen LE, Himes B and Weiner SB: Thymic squamous cell carcinoma. J Am Osteopath Assoc 91: 614-617, 1991.
21. Geffen DB, Benharroch D, Yellin A, Ariad S, Or R and Cohen Y: Multimodal treatment of metastatic thymic carcinoma including high-dose chemotherapy with autologous stem cell transplantation: report of a case with more than 4-year disease-free survival. Am J Clin Oncol 24: 566-569, 2001. (Pubitemid 33131416)
22. Ogawa K, Toita T, Uno T, et al: Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 94: 3115-3119, 2002. (Pubitemid 34670493)
23. Koizumi T, Takabayashi Y, Yamagishi S, et al: Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 25: 266-268, 2002. (Pubitemid 34602548)
24. Yoh K, Goto K, Ishii G, et al: Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 98: 926-931, 2003. (Pubitemid 37022091)